Furthermore, NY‐ESO‐1 expression has been associated with poor overall survival (OS) rates in MLS patients, highlighting its potential as both a diagnostic and prognostic marker for MLS among mesenchymal myxoid neoplasms.31 This evidence concerns the gene CTAG1B and McLeod neuroacanthocytosis syndrome.